Sheila Singh, MD, PhD, is a pediatric neurosurgeon and a Joint Head of the School of Cancer & Pharmaceutical Sciences and Head of the Comprehensive Cancer Centre at King’s College London.

Dr. Singh previously served as Director of the Surgeon-Scientist Program, the Pediatric Brain Tumour Study Group, and the Centre for Discovery in Cancer Research (CDCR) at McMaster University. 

Dr. Singh’s research focuses on aggressive primary brain tumors that typically affect children, including the dissection of the molecular mechanisms that drive tumor initiation. Her lab has established unique pipelines for discovery from human brain tumor samples and dissecting mechanisms that may be therapeutically targeted for this life-threatening condition. Her therapeutic areas of focus are tailored immunotherapies and molecular therapies, both for primary tumors and brain metastases. She has also established a unique clinical academic training program for surgeons, the McMaster Surgeon-Scientist Program. 

Dr. Singh received her MD from McMaster University. She became an ACGT Research Fellow in 2024 as part of a cross-institution collaboration focused on synthetic T-cell therapy for recurrent pediatric brain tumors, specifically medulloblastoma and ependymoma.